Swiss biopharmaceutical company AC Immune said a recent study concluded that its PET tracer showed potential for detecting and monitoring Parkinson's disease in humans.
The study was presented by Francesca Capotosti, PhD, of AC Immune at the International Conference on Alzheimer's and Parkinson's Diseases in Lisbon. The researchers found that the company's Morphomer a-syn PET tracer demonstrated excellent sensitivity for human Parkinson's disease-brain derived alpha-synuclein (a-syn), according to the company. AC Immune said it's now progressing with a phase I trial for the PET tracer.
In addition, AC Immune is also beginning preclinical development of its oral small-molecule Morphomer a-syn inhibitors and SupraAntigen a-syn antibodies as therapeutic candidates for Parkinson's and other related diseases.
